Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Cash from Financing Activities (2016 - 2023)

Spero Therapeutics' Cash from Financing Activities history spans 8 years, with the latest figure at $1000.0 for Q4 2023.

  • For Q4 2023, Cash from Financing Activities fell 99.99% year-over-year to $1000.0; the TTM value through Dec 2024 reached $221000.0, changed 0.0%, while the annual FY2023 figure was $221000.0, 100.75% up from the prior year.
  • Cash from Financing Activities reached $1000.0 in Q4 2023 per SPRO's latest filing, down from $220000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $77.2 million in Q3 2020 to a low of -$53.7 million in Q2 2022.
  • Average Cash from Financing Activities over 5 years is $11.2 million, with a median of $5.9 million recorded in 2019.
  • Peak YoY movement for Cash from Financing Activities: surged 772050.0% in 2020, then crashed 32050.6% in 2022.
  • A 5-year view of Cash from Financing Activities shows it stood at $5.6 million in 2019, then skyrocketed by 187.37% to $16.1 million in 2020, then surged by 212.92% to $50.3 million in 2021, then crashed by 71.84% to $14.2 million in 2022, then crashed by 99.99% to $1000.0 in 2023.
  • Per Business Quant, the three most recent readings for SPRO's Cash from Financing Activities are $1000.0 (Q4 2023), $220000.0 (Q3 2023), and $14.2 million (Q4 2022).